Article Data

  • Views 588
  • Dowloads 141

Original Research

Open Access

Polymorphisms of human papillomavirus type 16 E7 in Uyghur women with cervical cancer

  • Lin Wang1,†
  • Sulaiya Husaiyin1,†
  • Peifeng Xu1
  • Xiaoli Wang2
  • Lili Han1
  • Mayinuer Niyazi1,*,

1Department of Gynecology, Xinjiang Uyghur Autonomous Region People’s Hospital, 830001 Urumqi, China

2Maternal and Child Health Center of the Xinjiang Uyghur Autonomous Region, 830001 Urumqi, China

DOI: 10.31083/j.ejgo.2020.06.5469 Vol.41,Issue 6,December 2020 pp.1010-1015

Submitted: 29 January 2020 Accepted: 10 May 2020

Published: 15 December 2020

*Corresponding Author(s): Mayinuer Niyazi E-mail: mayinniya@163.com

† These authors contributed equally.

Abstract

Purpose: To analyse the association of HPVl6 E7 mutations with cervical cancer among Uyghur women in Xinjiang, China. Methods: From December 2008 to August 2010, 80 Uygur women who were confirmed to have cervical cancer were recruited. Cervical tissues were collected. DNA was extracted from the samples. HPVl6 L1 was amplified for the identification of tissues infected with HPV16. Polymerase chain reactions and DNA sequencing were then performed for polymorphism analysis of HPVl6 E7 in HPV16-infected tissues. Results: A total of 60 samples were confirmed to have HPV16 infection. Among these samples, 54 successfully underwent HPV16 E7 sequencing, and 6 were observed with E7 mutations. The locations of the mutations were A647G (2/54), T760C (2/54), G663A (1/54), G666A (1/54), C790T (1/54), and T846C (1/54). A647G (2/54) and C790T (1/54) were missense mutations. Conclusion: HPV16 E7 is conserved in Xinjiang with a relatively low mutation rate.

Keywords

Cervical cancer; Human papillomavirus type 16; E7 gene; Sequence analysis; Mutation.


Cite and Share

Lin Wang,Sulaiya Husaiyin,Peifeng Xu,Xiaoli Wang,Lili Han,Mayinuer Niyazi. Polymorphisms of human papillomavirus type 16 E7 in Uyghur women with cervical cancer. European Journal of Gynaecological Oncology. 2020. 41(6);1010-1015.

References

[1] Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.: “Global cancer statistics 2018: GLOBOCAN estimates of in-cidence and mortality worldwide for 36 cancers in 185 countries”. Ca. Cancer J. Clin., 2018, 68, 394-424.

[2] Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., et al.: “Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods”. Int. J. Cancer, 2019, 144, 1941-1953.

[3] World Health Organization.: “Human papillomavirus (HPV) and cervical cancer”. https://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed August 18, 2019.

[4] National Cancer Institute, US National Institutes of Health: “Human papillomaviruses and cancer: questions and answers”. http://www.cancer.govcancertopics/factsheet/Risk/HPV. Accessed April 28, 2008.

[5] US Food and Drug Administration: “FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus: rapid approval marks major advancement in public health”. FDA News 2006 June 8. http://www.fda. gov/bbs/topics/NEWS/2006 /NEW01385 .html. Accessed April 28, 2008.

[6] Wardak S.: “Human papillomavirus (HPV) and cervical cancer”. Med. Dosw. Mikrobiol., 2017, 68, 73-84.

[7] Lee S.J., Yang A., Wu T., Hung C.F.: “Immonotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research”. J. Gynecol. Oncol., 2016, 27, e51.

[8] Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., et al.: “Global burden of human papillo-mavirus and related diseases”. Vaccine, 2012, 30, F12-F23.

[9] Cohen P.A., Jhingran A., Oaknin A., Denny L.: “Cervical cancer”. Lancet, 2019, 393, 169-182.

[10] Krashias G., Koptides D., Christodoulou C.: “HPV prevalence and type distribution in cypriot women with cervical cytological abnormalities”. BMC Infect. Dis., 2017, 17, 346.

[11] Muñoz N., Castellsagué X., de González A.B., Gissmann L.: “Chapter 1: HPV in the etiology of human cancer”. Vaccine, 2006, 24, S1-S10.

[12] Stanley M.: “Immunobiology of HPV and HPV vaccines”. Gynecol. Oncol., 2008, 109, S15-S21.

[13] Boulet G., Horvath C., Broeck D.V., Sahebali S., Bogers J.: “Human papillomavirus: E6 and E7 oncogenes”. Int. J. Biochem. Cell Biol., 2007, 39, 2006-2011.

[14] Fan X., Liu Y., Heilman S.A., Chen J.J.: “Human papillomavirus E7 induces rereplication in response to dna damage”. J. Virol., 2013, 87, 1200-1210.

[15] Narisawa-Saito M., Kiyono T.: “Mechanisms of high-risk hu-man papillomavirus-induced cervical carcinogenesis”. Nihon Rinsho. Japanese Journal of Clinical Medicine, 2009, 67, 53-61.

[16] Jun-Qi M., Hatila T., Shu-Juan J., Jian-He Z., Jing-Bao X., Ayshamgul H.: “Functional role of NRF2 in cervical carcinogenesis”. PLoS One, 2015, 10, e0133876.

[17] Yang B.H., Bray F.I., Parkin D.M., Sellors J.W., Zhang Z.: “Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost”. Int. J. Cancer, 2004, 109, 418-424.

[18] Guzalinuer A., Peng Z., Guo Y.: “HPV and its subtypes in the Han nationality in Sichuan and the northwestern region of Xinjiang Uyghur Southern region of cervical tissue of women differentially expressed”. Chin. J. Microbiol. Immunol., 2004, 24, 402-406.

[19] Suzuke L., Peng Y., Zhou K.: “The analysis of pathogenetic tendency of cervical cancer in various ethnic groups in Xinjiang”. J. Xinjiang Med. Univ., 2006, 29, 569-571.

[20] Vajpeyi R.: “WHO classification of tumours: pathology and genetics of tumours of the breast and female genital organs”. J. Clin. Pathol., 2005, 76, 139-141.

[21] Chan S.Y., Ho L., Ong C.K., Chow V., Drescher B., Dürst M., et al.: “Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind.”. J. Virol., 1992, 66, 2057-2066.

[22] Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F. X., et al.: “Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.”. J. Virol., 1997, 71, 2463-2472.

[23] Rodríguez-Ruiz H.A., Garibay-Cerdenares O.L., Illades-Aguiar B., Montaño S., Jiang X., Leyva-Vázquez M.A.: “In silico prediction of structural changes in human papillomavirus type 16 (HPV16) E6 oncoprotein and its variants”. BMC Mol. Cell Biol., 2019, 20, 35.

[24] Yang L., Yang H., Wu K., Shi X., Ma S., Sun Q.: “Prevalence of HPV and variation of HPV 16/HPV 18 E6/E7 genes in cervical cancer in women in South West China”. J. Med. Virol., 2015, 86, 1926-1936.

[25] Zhou Z., Yang H., Yang L., Yao Y., Dai S., Shi L., et al.: “Human papillomavirus type 16 E6 and E7 gene variations associated with cervical cancer in a Han Chinese population”. Infect. Genet. Evol., 2019, 73, 13-20.

[26] Zhe X., Xin H., Pan Z., Jin F., Zheng W., Li H., et al.: “Genetic variations in E6, E7 and the long control region of human papillo-mavirus type 16 among patients with cervical lesions in Xinjiang, China”. Cancer Cell Int., 2019, 19, 65.

[27] Park J.S., Shin S., Kim E.C., Kim J.E., Kim Y.B., Oh S., et al.: “As-sociation of human papillomavirus type 16 and its genetic variants with cervical lesion in Korea”. Apmis., 2016, 124, 950-957.

[28] Mosmann J.P., Monetti M.S., Frutos M.C., Kiguen A.X., Venezuela R.F. and Cuffini C.G.: “Mutation detection of E6 and LCR genes from HPV 16 associated with carcinogenesis”. Asian Pac. J. Cancer Prev., 2015, 16, 1151-1157.

[29] Berezutskaya E.B., Yu B., Morozov P., Raychaudhuri P.: “Differentiation regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein”. Cell Growth Differ., 1997, 8, 1277-1286.

[30] McLaughlin-Drubin M.E., Huh K., Münger K.: “Human papillo-mavirus type 16 E7 oncoprotein associates with E2F6”. J. Virol., 2008, 82, 8695-8705.

[31] McLaughlin-Drubin M.E., Münger K.: “The human papillomavirus E7 oncoprotein”. Virology, 2009, 384, 335-344.

[32] Mighty K.K., Laimins L.A.: “The role of human papillomaviruses in oncogenesis”. Viruses and Human Cancer, 2014, 19, 135-148.

[33] van Duin M., Meijer C.J.L.M., Walboomers J.M.M., Verheijen R.H.M., Helmerhorst T.J., Snijders P.J.F., et al.: “Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis”. J. Gen. Virol., 2000, 81, 317-325.

[34] Tornesello M.L., Duraturo M.L., Salatiello I., Buonaguro L., Los-ito S., Botti G., et al.: “Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer”. J. Med. Virol., 2004, 74, 117-126.

[35] Song Y.S., Kee S.H., Kim J.W., Park N.H., Kang S.B., Chang W.H., et al.: “Major sequence variants in E7 gene of human papillomavirus type 16 from cervical cancerous and noncancerous lesions of korean women”. Gynecol. Oncol., 1997, 66, 275-281.

[36] de Boer M.A., Peters L.A.W., Aziz M.F., Siregar B., Cornain S., Vrede M.A., et al.: “Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands”. Gynecol. Oncol., 2004, 94, 488-494.

[37] Wu Y., Chen Y., Li L., Yu G., He Y., Zhang Y.: “Analysis of muta-tions in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China”. J. Gen. Virol., 2006, 87, 1181-1188.

[38] Shang Q., Wang Y., Fang Y., Wei L.L., Chen S.J., Sun Y.H., et al.: “Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in cervical carcinomas in patients in northeast China”. J. Clin. Microbiol., 2011, 49, 2656-2663.

[39] Duensing S., Münger K.: “The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability”. Cancer Res., 2003, 62, 7075-7082.

[40] Hua W., Hongbing C.: “Polymorphisms of E7 and E5 genes in human papillomavirus type among patients with cervical cancer in hubei province of China”. Med. J. Wuhan Univ., 2009, 30, 759-762.

[41] Liu X., Liu G., Pang Z., Xing F.: “Sequence polymorphism of hu-man papillomavirus type 16 E7 in cervical cancer”. Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the first Medical College of PLA, 2007, 25, 1272-1275.

[42] Yang Y.J., Zhao J., Liao Q.P.: “Association between human papil-lomavirus (HPV) type 16 infection and E6/E7 gene variant and the cervical lesions in Beijing”. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2007, 21, 32-34.

[43] Chan P.K., Lam C.W., Cheung T.H., Li W.W.H., Lo Keith W.K., Chan M.Y.M., et al.: “Human papillomavirus type 16 intratypic variant infection and risk for cervical neoplasia in southern China”. Infect. Dis., 2002, 186, 696-700.

[44] Choi B.S., Kim S.S., Yun H., Jang D.H., Lee J.S.: “Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers”. Med. Virol., 2007, 79, 426-430.

[45] Pande S., Jain N., Prusty B.K., Bhambhani S., Gupta S., Sharma R., et al.: “Human papillomavirus type 16 variant analysis of E6, E7, and L1 genesand long control region in biopsy samples from cervical cancer patients in north India”. Clin. Microbiol., 2008, 46, 1060-1066.

[46] Safaeian M., van Doorslaer K., Schiffman M., Chen Z.G., Rodriguez A.C., Herrero R., et al.: “Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties”. Arch. Virol., 2010, 155, 367-370.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top